Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

ClinicalTrials.gov ID: NCT06547216

Public ClinicalTrials.gov record NCT06547216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Study identification

NCT ID: NCT06547216
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Avidity Biosciences, Inc.; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Interventions

AOC 1020 Drug

Drug

Eligibility (public fields only)

Age range: 16 Years to 72 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 24, 2024
Primary completion: Mar 31, 2030
Completion: May 31, 2030
Last update posted: Jul 13, 2026

2024 – 2030

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California Los Angeles	Los Angeles	California	90095	—
Stanford University	Palo Alto	California	94304	—
University of California San Diego	San Diego	California	92093	—
University of Colorado	Denver	Colorado	80045	—
University of Florida	Gainesville	Florida	32608	—
Rare Disease Research	Atlanta	Georgia	30329	—
Kansas University Medical Center	Kansas City	Kansas	66205	—
University of Rochester Medical Center	Rochester	New York	14642	—
Duke University	Durham	North Carolina	27708	—
Ohio State University	Columbus	Ohio	43221	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
University of Texas Southwestern	Dallas	Texas	75390	—
Virginia Commonwealth University	Richmond	Virginia	23298	—
University of Washington	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06547216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 13, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06547216 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →